| Authors: |
Costa LJ; Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL., Davies FE; Myeloma Research Program, Perlmutter Cancer Center, NYU Langone, New York, NY., Monohan GP; Division of Hematology and Blood & Marrow Transplant, University of Kentucky, Lexington, KY., Kovacsovics T; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT., Burwick N; Division of Hematology, University of Washington, Seattle, WA., Jakubowiak A; Myeloma Program, The University of Chicago Medicine, Chicago, IL., Kaufman JL; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA., Hong WJ; Genentech, Inc, South San Francisco, CA., Dail M; Genentech, Inc, South San Francisco, CA., Salem AH; AbbVie, Inc, North Chicago, IL.; Department of Clinical Pharmacy, Ain Shams University, Cairo, Egypt., Yang X; AbbVie, Inc, North Chicago, IL., Masud AA; AbbVie, Inc, North Chicago, IL., Munasinghe W; AbbVie, Inc, North Chicago, IL., Ross JA; AbbVie, Inc, North Chicago, IL., Bueno OF; AbbVie, Inc, North Chicago, IL., Kumar SK; Division of Hematology, Mayo Clinic, Rochester, MN; and., Stadtmauer EA; Division of Hematology and Oncology, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA. |
